https://scholars.lib.ntu.edu.tw/handle/123456789/582252
標題: | Recent research progress in hepatocellular carcinoma | 作者: | JIA-HORNG KAO DING-SHINN CHEN |
關鍵字: | Cirrhosis; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Prognosis; Screening | 公開日期: | 2002 | 卷: | 101 | 期: | 4 | 起(迄)頁: | 239-248 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Hepatocellular carcinoma (HCC) is responsible for significant morbidity and mortality throughout the world, and is clearly linked to viral infections. Mass vaccination programs against hepatitis B virus have reduced the incidence of HCC in Taiwanese children, and are likely to yield similar benefits elsewhere. In many countries, a definite increase in the incidence of HCC has been reported, largely attributable to the increasing incidence of hepatitis C virus infection. Although the major viral and environmental risk factors for the development of HCC have been determined, the oncogenic pathways leading to malignant transformation of liver cells have long remained obscure. HCC is also extremely difficult to manage. Although patients at risk can be identified and early detection of HCC is feasible, the current management of HCC is confusing due to the lack of well-designed, randomized clinical trials comparing various treatment modalities. New surgical techniques and postoperative therapies may improve the outcome in some resectable cancers; however, the vast majority of patients have unresectable tumors. Local ablation treatments may shrink or necrose tumors, but the clear benefit of such therapies remains to be seen. Further elucidation of the genetic and molecular features of HCC may lend insight that will lead to the development of innovative strategies to manage this cancer. In this article, the current understanding of HCC with respect to etiologic factors, genetic mechanisms responsible for hepatocarcinogenesis, diagnosis, therapy, and prevention are reviewed. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036302555&partnerID=40&md5=e515cce2e20e60acd073a400f0895c86 https://scholars.lib.ntu.edu.tw/handle/123456789/582252 |
ISSN: | 0929-6646 | SDG/關鍵字: | alpha interferon; antineoplastic agent; antivirus agent; curcumin; cytotoxic agent; hepatitis B vaccine; hepatitis C vaccine; interferon; lamivudine; nucleoside analog; ribavirin; antiviral activity; cancer incidence; cancer research; cancer risk; clinical study; controlled study; drug efficacy; drug formulation; drug safety; drug tolerability; early diagnosis; environmental factor; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; liver carcinogenesis; liver cell carcinoma; malignant transformation; morbidity; mortality; postoperative care; review; risk factor; surgical technique; Taiwan; treatment outcome; tumor necrosis; vaccination; virus infection; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Prognosis |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。